Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.57 |
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.57 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 4/20 | 0.49 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.48 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812579 | 1.00 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL11415082 | 1.00 | LAP3 (0.57) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL21570273 | 0.92 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL21570275 | 0.92 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL5812534 | 0.92 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL5812528 | 0.92 | LAP3 (0.55) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL13427297 | 0.90 | HDAC3 (0.55) | LAP3ANPEPRNPEPDNPEPHDAC3 | |
| SCHEMBL11414316 | 0.88 | MME (0.61) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL11414321 | 0.88 | MME (0.61) | LAP3ANPEPRNPEPDNPEPMME | |
| SCHEMBL11412768 | 0.87 | NAALAD2 (0.63) | LAP3ANPEPRNPEPDNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4189604-A | PEPTIDASE ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-02-19 | — | — | US | claimed |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-4453003-A | ENZYME INHIBITORS, ANTIINFLAMMATORY AGENTS | UMEZAWA HAMAO (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4391986-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-07-05 | — | — | US | disclosed |
| US-4281180-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-07-28 | — | — | US | disclosed |
| US-4240975-A | USED AS ENZYME INHIBITOR, ANTIFERTILITY AGENT, AND ENHANCES THE ANTITUMOR EFFECT OF BLEOMYCIN | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-12-23 | — | — | US | disclosed |
| US-4189604-A | PEPTIDASE ENZYME INHIBITORS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | LAP3 4399/4885ANPEP 2125/4885RNPEP 925/4885 |
| US-20190350917-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | LAP3 440/4885ANPEP 872/4885RNPEP 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.